While considered an established marker of cell proliferation for decades, the potential role for Ki67 immunohistochemistry (IHC) in breast cancer management has remained unclear due largely to its high inter-observer variability and the lack of established cutoff points for clinical decisions [1]. This evidence concerns the gene MKI67 and breast carcinoma.